Catalan pharmaceutical Grifols to buy 45% of California-based Alkahest for almost $40 million
Grifols, a global healthcare company based in Greater Barcelona, announced on Wednesday that it will acquire 45% of the California-based firm Alkahest for $37.5 million. The biopharmaceutical company headquartered in Redwood City (near San Francisco) was founded last year upon the work of Stanford University scientists, who proved that factors in the blood of young animals were able to restore mental capabilities in old animals. This discovery has triggered Grifols' interest, a world leader in blood-derivative products. The two partners will work together on the development of novel plasma-based products for the treatment of cognitive impairment associated with age and other diseases of the central nervous system, including Alzheimer´s.